Table 1. Characteristics of Patients Receiving an ICD Among Secondary Prevention Randomized Controlled Trials
AVID (n=507)30CASH (n=99)31CIDS (n=328)32
Inclusion
  1. Patients resuscitated from near‐fatal VF

  2. Sustained VT with syncope

  3. Sustained VT with an LVEF <40% and symptoms suggesting severe hemodynamic compromise due to the arrhythmia

  1. Patients resuscitated from cardiac arrest secondary to documented sustained ventricular arrhythmias

  1. Documented VF

  2. Out‐of‐hospital cardiac arrest requiring defibrillation or cardioversion

  3. Documented, sustained VT causing syncope

  4. Documented, sustained VT at a rate >150 beats/min causing presyncope or angina in a patient with LVEF <35%

  5. Unmonitored syncope with subsequent documentation of either spontaneous VT >10 seconds or sustained monomorphic VT induced by programmed ventricular stimulation

Mean age (SD)65±1158±1163±9.2
Male, %787985
Coronary artery disease, %8173···
LVEF (%, SD)32±1346±1934.3±14.5
NYHA
 I or II, %488237.8
 III, %718···
Presenting arrhythmia
 Ventricular fibrillation, %448447
 Ventricular tachycardia, %
 Sustained VT5516···
 VT with syncope······13
 Other VT······25
Medications
 β‐Blocker38.1% (ICD); 11% (AAD) at 12 months0 in ICD or amiodarone arm37% (ICD); 21.2% (AAD) at 12 months
 Angiotensin‐converting enzyme inhibitor68.4% (ICD); 65.5% (AAD) at 12 months40% to 45% at dischargeNot recorded
 Digitalis45.8% (ICD); 37.9% (AAD) at 12 months15% to 26% at discharge34.5% (ICD); 21.9% (AAD) at 12 months
 Diuretic agent56% (ICD); 59.3% (AAD) at 12 months25% to 33% at dischargeNot recorded
 Mineralocorticoid receptor antagonistNot recordedNot recordedNot recorded
  • AAD indicates antiarrhythmic drug; AVID, Antiarrhythmics Versus Implantable Defibrillators; CASH, Cardiac Arrest Study Hamburg; CIDS, Canadian Implantable Defibrillator Study; ICD, implantable cardioverter defibrillator; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; VF, ventricular fibrillation; VT, ventricular tachycardia.